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INTRODUCTION
‘Collaboration is key’ was the message from this 
symposium. Fittingly, there was great breadth in 
contributions from nephrology, other medical specialties, 
intensive care, and psychiatry, and global webstreaming 
to international delegates in 18 countries.
RENAL AND RHEUMATOLOGY
Vasculitis is a challenging multisystem condition to treat, 
but often lethal without treatment. Dr Neil Basu 
(University of Aberdeen) described his experience as a 
rheumatologist in a multidisciplinary vasculitis service. 
Close partnership of neighbouring specialties offers 
distinct advantages. ‘Joints are the window to the 
immune system’, for instance, and attention to joint pain 
can improve the early recognition of relapses. For the 
patient, a multidisciplinary service causes less duplication 
and mixed messages. The overall service also benefits 
from a single regional disease register facilitating quality 
improvement; and clinicians benefit from up-skilling by 
learning alongside colleagues with experience in other 
fields. Dr Basu also summarised recent clinical research 
into immunosuppression regimes in ANCA vasculitis 
and lupus. A variety of therapeutic options exist but 
tellingly he highlighted our inability to stratify patients 
into targeted regimes and predict when managed drug 
withdrawal might be successful.
Professor Christopher Dewton (Royal Free Hospital 
and UCL) picked up the theme of stratification in the 
treatment of systemic sclerosis, another heterogeneous 
multisystem condition. Screening for organ complications 
is the cornerstone of management. Different organ 
complications are associated with different baseline 
autoantibody profiles (centromere with pulmonary 
hypertension, topoisomerase-1 (scl-70) with lung fibrosis, 
RNA polymerase-III with scleroderma renal crisis), 
which could help risk stratify patients for therapy. While 
renal crises are readily treatable with ACE inhibitors, the 
treatment of other complications remains a challenge. A 
difficulty with pulmonary arterial hypertension is delayed 
diagnosis and Professor Dewton introduced the 
‘DETECT’ two step bedside risk calculator, which has 
the potential to improve early referral for right heart 
catheterisation.1 In addition, he highlighted patients with 
progressive lung fibrosis who are among those with the 
worst prognosis. Cyclophosphamide, mycophenolate 
mofetil and rituximab are the main treatment options, 
with a possible selective option of autologous stem cell 
transplantation as rescue therapy.
Professor David Reid (University of Aberdeen) 
discussed the management of osteoporosis and renal 
disease. Whereas the management in chronic kidney 
disease (CKD) stages 1–3 can be guided by standard 
risk calculators incorporating bone density and other 
risk factors, the decision-making in advanced CKD, 
transplant and chronic dialysis patients is more 
complex. Bone quality in advanced CKD is frequently 
poor. Renal bone disease includes a spectrum from 
high bone turnover to adynamic bone disease, vascular 
calcification is also common, and transplant patients 
suffer additional bone loss from glucocorticoids. 
Bisphosphonates, denosumab, and the newer anabolic 
agent teriparatide may all have roles, but evidence on 
which to make firm statements in advanced CKD 
remains lacking.2
RENAL AND DERMATOLOGY
Dr Richard Weller (Edinburgh Royal Infirmary) 
introduced his research by proposing another renal 
relevance for skin and the sun (other than skin 
cancers in transplant patients) – as a regulator of 
blood pressure. Increased latitude and the winter 
season relate inversely to blood pressure and 
cardiovascular death through a mechanism seemingly 
independent of vitamin D. One explanation is that the 
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skin modulates nitric oxide bioavailability in response 
to UVA irradiation leading to systemic arterial 
vasodilatation.3
The keynote lecture was from Professor Markus Ketteler 
(Klinikum Coburg, Germany) on calciphylaxis, or ‘calcific 
uremic arteriolopathy’. This is a painful skin condition 
with high mortality that typically affects dialysis patients. 
It involves the calcification of small cutaneous arterioles 
and nerve sheaths, evolving into necrotic ulcers. The 
epidemiology is not well understood and Professor 
Ketteler introduced findings from the German 
Calciphylaxis Registry. The links between warfarin use, 
vitamin K2 deficiency and vascular calcification were 
particularly notable, but heterogeneity of the condition 
was also apparent, and this highlights the need for more 
collaborative registry data collection.4
RENAL AND HEPATOLOGY
Professor Julia Wendon (Kings College London) provided 
an update of the mechanisms and classification of 
hepatorenal syndrome (HRS), describing HRS type 1 as 
a subset of acute kidney injury,5 and HRS type 2 as a 
subset of CKD. Renal impairment can go unrecognised 
in liver disease due to low creatinine from reduced 
muscle and liver creatine production. She pointed to the 
prognostic importance of the cause of renal impairment 
when assessing the potential for recovery and a role of 
selective abdominal paracentesis to improve renal 
perfusion pressure. Finally, she illustrated how prognostic 
scoring tools may perform well with overall groups of 
patients but are much more difficult to use in clinical 
decision making for the individual patient in need of 
intensive care.
Dr Stephen Barclay (Glasgow Royal Infirmary) updated 
us on the management of hepatitis C. Sixteen percent of 
chronically infected patients develop cirrhosis by 20 
years and they also have double the risk of developing 
end-stage kidney disease. Fibroscan is the standard 
method of assessing severity, but an AST:ALT >1 in the 
absence of alcohol is also suggestive of fibrotic liver 
disease. New antivirals have dramatically increased the 
cure rates and treatment should be considered both in 
dialysis and renal transplant patients.
NEPHROLOGY AND PsYCHIATRY
An overview of lithium nephrotoxicity was provided by 
Dr Charlie Tomson (Freeman Hospital, Newcastle upon 
Tyne). Lithium is the first-line treatment for bipolar 
mood disorder. It frequently causes reversible 
nephrogenic diabetes insipidus, but with prolonged use 
renal damage can become progressive with microcysts 
visible on MRI. Key learning points were to not overlook 
a central cause in those with diabetes insipidus and the 
potential therapeutic use of amiloride. Of note, there is 
clear randomised controlled trial evidence that lithium 
prevents suicide and self-harm in people with unipolar 
and bipolar mood disorders and therefore any discussions 
on withdrawing lithium to avoid renal progression 
require care.
Professor Michael Eddleston (National Poisons 
Information Service) discussed the role of nephrology in 
acute poisoning. Using a case of lithium as one of several 
examples, he discussed concepts of volume of distribution, 
drug clearance and the need to monitor for post-dialysis 
rebound toxicity.
The symposium closed with Dr Stephen Potts (Edinburgh 
Royal Infirmary) who discussed several cases pointing to 
the need for psychiatry input embedded within the renal 
team. In particular, he painted an unsettling illustration of 
‘dialysis as purgatory’, and described how renal patients 
are ‘different’. He explained the ambivalent dependence 
of dialysis patients on staff and treatments that are 
simultaneously both lifesaving and a cause of thrice 
weekly ‘torture’. The need for access to support outside 
the dialysis unit is therefore clear if patients are to have 
adequate opportunity to vent their frustrations.
TAKE HOME MEssAGE
People with kidney disease are indeed ‘different’. They 
are a vulnerable heterogeneous group with multimorbidity 
who often receive toxic therapies. This symposium 
demonstrated how a team approach involving other 
specialties is regularly essential, particularly as a strong 
evidence base is frequently lacking or difficult to apply to 
individual renal patients. Risk-stratification was a 
recurring theme either as a necessity or as an exciting 
hope for the future. Novel biomarkers and therapeutic 
agents may enable us to provide more tailored care in 
multisystem diseases, but the stratification of 
multimorbidity remains challenging and highlights our 
need for collaborative care.
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